Allogene Therapeutics (ALLO) News Today $2.27 -0.19 (-7.72%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period William Blair Reaffirms Outperform Rating for Allogene Therapeutics (NASDAQ:ALLO)November 17 at 2:22 AM | americanbankingnews.comPiper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)November 14 at 4:34 PM | markets.businessinsider.comAllogene Therapeutics price target lowered to $9 from $11 at Piper SandlerNovember 14 at 4:34 PM | markets.businessinsider.comStrategic Resource Reallocation and Growth Focus Underpin Buy Rating for Allogene TherapeuticsNovember 14 at 11:30 AM | markets.businessinsider.comAllogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst DowngradeAllogene Therapeutics (NASDAQ:ALLO) Trading Down 6.3% on Analyst DowngradeNovember 14 at 11:05 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Given New $9.00 Price Target at Piper SandlerPiper Sandler decreased their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday.November 14 at 8:47 AM | marketbeat.comStifel Nicolaus Sticks to Its Hold Rating for Allogene Therapeutics (ALLO)November 13, 2024 | markets.businessinsider.comAllogene Therapeutics' (ALLO) "Buy" Rating Reaffirmed at HC WainwrightNovember 12, 2024 | americanbankingnews.comJMP Securities Remains a Hold on Allogene Therapeutics (ALLO)November 11, 2024 | markets.businessinsider.comAllogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)November 8, 2024 | markets.businessinsider.comAllogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...November 8, 2024 | finance.yahoo.comPromising Efficacy and Strategic Advancements Propel Allogene Therapeutics to a Buy RatingNovember 8, 2024 | markets.businessinsider.comAllogene Therapeutics’ Promising Clinical Trial Advances and Strategic Positioning: A Buy Recommendation by Tyler Van BurenNovember 8, 2024 | markets.businessinsider.comAllogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comAllogene Therapeutics Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comAllogene announces Phase 1 data on ALLO-316 in advanced RCCNovember 7, 2024 | markets.businessinsider.comAllogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateNovember 7, 2024 | markets.businessinsider.comAllogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateNovember 7, 2024 | globenewswire.comAllogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCSNovember 7, 2024 | globenewswire.comAllogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comAllogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetingsNovember 5, 2024 | markets.businessinsider.comAllogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 5, 2024 | globenewswire.comAllogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Time to Buy?Allogene Therapeutics (NASDAQ:ALLO) Trading 6.3% Higher - Here's What HappenedNovember 4, 2024 | marketbeat.comAllogene Therapeutics (ALLO) Set to Announce Earnings on ThursdayAllogene Therapeutics (NASDAQ:ALLO) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.October 31, 2024 | marketbeat.comAllogene Therapeutics' (ALLO) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comAllogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business UpdateOctober 30, 2024 | globenewswire.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received an average recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating oOctober 29, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6% - Time to Buy?Allogene Therapeutics (NASDAQ:ALLO) Shares Up 6.6% - Here's WhyOctober 28, 2024 | marketbeat.comRefractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 28, 2024 | theglobeandmail.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.4% - What's Next?Allogene Therapeutics (NASDAQ:ALLO) Trading Down 5.4% - Time to Sell?October 24, 2024 | marketbeat.comZacks Research Issues Optimistic Forecast for ALLO EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities researchers at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research note issued on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts thatOctober 24, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)October 16, 2024 | markets.businessinsider.comThe Manufacturers Life Insurance Company Has $1.12 Million Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)The Manufacturers Life Insurance Company increased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 70.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 480,381 shares of the company's stock after buying an additional 1October 13, 2024 | marketbeat.comDimensional Fund Advisors LP Buys 507,021 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Dimensional Fund Advisors LP increased its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 24.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,550,640 shares of the company's stock after purchasingOctober 9, 2024 | marketbeat.comAllogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market ActivityOctober 2, 2024 | gurufocus.comAllogene Therapeutics (NASDAQ:ALLO) Trading Down 6.4%Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 6.4%October 1, 2024 | marketbeat.comAllogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day ConferenceSeptember 30, 2024 | globenewswire.comPerceptive Advisors LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Perceptive Advisors LLC purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,725,000 shares of the company's stock, valued at approximately $6,3September 30, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Renaissance Technologies LLCRenaissance Technologies LLC boosted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 340.4% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 1,747,955 shares of the company's stock after acquiring an additionSeptember 29, 2024 | marketbeat.comAllogene reveals next-gen CAR T candidate for autoimmune diseaseSeptember 28, 2024 | uk.investing.comLynx1 Capital Management LP Invests $5.19 Million in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Lynx1 Capital Management LP acquired a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,228,295 shares of the company's stSeptember 27, 2024 | marketbeat.comZacks Research Equities Analysts Increase Earnings Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO)Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at Zacks Research raised their Q1 2026 earnings per share estimates for Allogene Therapeutics in a research note issued on Wednesday, September 18th. Zacks Research analyst R. Department now anticipates that the company willSeptember 23, 2024 | marketbeat.comPrimecap Management Co. CA Increases Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Primecap Management Co. CA lifted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 4.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,670,226 shares of thSeptember 19, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Trading 3.1% Higher Allogene Therapeutics (NASDAQ:ALLO) Trading Up 3.1%September 18, 2024 | marketbeat.comAllogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer StockSeptember 15, 2024 | msn.comTD Asset Management Inc Acquires 361,904 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)TD Asset Management Inc grew its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 82.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 799,340 shares of the company's stockSeptember 14, 2024 | marketbeat.comAllogene Therapeutics Inc ALLOSeptember 13, 2024 | morningstar.comAllogene Therapeutics (NASDAQ:ALLO) Shares Down 4.8% Allogene Therapeutics (NASDAQ:ALLO) Shares Down 4.8%September 12, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Trading Up 5.6%Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 5.6%September 10, 2024 | marketbeat.com Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.170.56▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼124▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FATE News Today BLUE News Today CGON News Today SWTX News Today SRRK News Today VCEL News Today BEAM News Today RXRX News Today NMRA News Today TARS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts